Celltrion Pharm, Inc. (068760.KQ) Stock
Celltrion Pharm, Inc.

Company profile
Celltrion Pharm reported revenue of 477.84 billion KRW for fiscal year 2024, up 22.9% from fiscal year 2023, and net income of 21.97 billion KRW. That is a net profit margin of 4.6% for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 131.30 billion KRW, up 12.1% from a year before. In Q2 2025 it reported net income of 11.09 billion KRW, against net income of 5.59 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 386.04 billion KRW in fiscal year 2022 to 477.84 billion KRW in fiscal year 2024, 11.3% a year on average.
What stands out
- Its net profit margin over the last four reported quarters was 9.5%, against a median of -8.9% for 6 listed companies of similar size in its industry.
- Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Celltrion Pharm, Inc.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operates as a subsidiary of Celltrion, Inc.
Largest shareholders
- Celltrion, Inc.55.89%
- Ok-jin Cheon0.0529 %0.05%
- LähiTapiola Varainhoito Oy0.03%
- Eon-Hyung Lee0.0224 %0.02%
- State Street Global Advisors Ltd.0.02%
Share of the company, as of September 25, 2026
Leadership
- Yoo Young-Ho — CEO & Executive Director
- Sang-Suk Kim — President
In the news
How much revenue does Celltrion Pharm make?
Celltrion Pharm reported 477.84 billion KRW in revenue for fiscal year 2024, up 22.9% from 388.79 billion KRW in fiscal year 2023. In Q2 2025 revenue was 131.30 billion KRW.
What companies are similar to Celltrion Pharm?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hanall Biopharma Co., Ltd. (009420.KS), LigaChem Biosciences Inc. (141080.KQ), Hugel, Inc. (145020.KQ), OliX Pharmaceuticals, Inc (226950.KQ).
How does Celltrion Pharm's profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Celltrion Pharm, 9.5%; Hanall Biopharma Co., Ltd. (009420.KS), -15.3%; LigaChem Biosciences Inc. (141080.KQ), -180.9%; Hugel, Inc. (145020.KQ), 26.4%; OliX Pharmaceuticals, Inc (226950.KQ), -102.9%; GC Biopharma Corp. (006280.KS), -2.5%; Daewoong Pharmaceutical Co., Ltd (069620.KS), 12.0%.
How has Celltrion Pharm's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 233.57 billion KRW; FY2021, 398.74 billion KRW; FY2022, 386.04 billion KRW; FY2023, 388.79 billion KRW; FY2024, 477.84 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Celltrion Pharm, Inc. (068760.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/068760.KQ